Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences President and CEO, Derek J. Maetzold, reported the sale of 509 shares of common stock at a weighted-average price of $40.04 per share under a pre-arranged 10b5-1 plan.

Summary

• Derek J. Maetzold, President and Chief Executive Officer and a Director of Castle Biosciences Inc., sold 509 shares of common stock.
• The transaction occurred on December 17, 2025, at a weighted-average price of $40.04 per share, with trades ranging from $40.00 to $40.08.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted by Mr. Maetzold on May 8, 2025.
• Following this transaction, Mr. Maetzold directly beneficially owns 34,360 shares of common stock.
• Additionally, Mr. Maetzold indirectly beneficially owns 261,372 shares through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, several Maetzold 2018 Remainder Trusts, and DJM Grantor Retained Annuity Trusts.

Sentiment

Score: 4

Explanation: The sale of shares by a CEO, even under a 10b5-1 plan, is generally viewed with slight negativity as it reduces direct ownership. However, the pre-scheduled nature mitigates concerns about opportunistic selling.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating it was not a discretionary sale based on recent non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived as a negative signal regarding management's confidence in the company's near-term stock performance.
• The CEO reduced direct beneficial ownership by 509 shares.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context.

Stakeholder Impact

• Shareholders may interpret the insider sale, even if pre-planned, as a slight negative signal regarding management's confidence, potentially leading to minor downward pressure on the stock price.

Key Dates

Recommendation

While the CEO's sale of shares is a reduction in direct ownership, it was conducted under a pre-arranged 10b5-1 plan, which suggests a systematic approach to personal financial management rather than a reaction to new negative information. The relatively small number of shares sold (509) compared to the total beneficial ownership (over 295,000 shares) indicates it's not a significant divestment. Therefore, the filing alone does not warrant a change from a 'hold' position, as it doesn't present new fundamental information about the company's operations or prospects.

Keywords

Castle Biosciences, CSTL, Derek J. Maetzold, Insider Sale, Form 4, SEC Filing, Beneficial Ownership, 10b5-1 Plan, Equity Transaction